MOLCURE, a Japanese biotechnology company specializing in AI-driven drug discovery for antibodies and peptides, announced a multi-year strategic research agreement with Boehringer Ingelheim on October 7th. The deal will see Boehringer implement MOLCURE’s platform technology to speed discovery of antibody therapeutics for multiple undisclosed targets. Financial details of the partnership were undisclosed. According to a company press release, MOLCURE’s proprietary platform is based on a large language model designed for antibody engineering. The partnership will see the companies combine wet-lab data with in silico modeling to enable the design of novel antibody sequences. Per the release, the companies hope that this will accelerate the discovery of antibody candidates relative to traditional processes.“We are delighted that Boehringer Ingelheim has chosen MOLCURE as a partner in recognition of our AI technology’s ability to deliver strong results from limited data,” said Satoshi Tamaki, CEO and CSO, MOLCURE, in the release. “We are excited to work alongside Boehringer Ingelheim’s scientists to further evolve our innovative AI-driven antibody discovery platform and make a significant contribution to their drug discovery programs. I hope that our partnership will lead to new treatments that improve the prognosis and quality of life for patients around the world.” Boehringer and MOLCURE enter antibody research partnership NEWS “BTK inhibition is a validated mechanism for the treatment of progressive forms of MS, and there is immense scientific interest in its potential to impact inflammation compartmentalized in the CNS and thereby potentially impact disability progression independent of relapse activity,” said Lisa von Moltke, M.D., Head of Research and Development, Chief Medical Officer, Zenas BioPharma, in the release. “We believe the differentiated, potentially best-in-class profile of orelabrutinib could make a meaningful difference for patients with PPMS and SPMS, which have few treatment options. With our late-stage development capabilities and expertise in MS, we are well positioned to execute on the pivotal, global, Phase III development of orelabrutinib, as well as advance two early candidates into clinical development.”
RkJQdWJsaXNoZXIy MjY2OTA4MA==